S119: PRELIMINARY RESULTS OF A PHASE 1 STUDY IN HEALTHY SUBJECTS ADMINISTERED INCLACUMAB, A FULLY HUMAN IGG4 ANTI-P-SELECTIN MONOCLONAL ANTIBODY IN DEVELOPMENT FOR TREATMENT OF SICKLE CELL DISEASE

• C Mayer,
• D Cooper,
• A Redfern,
• X Geng,
• J Shi,
• M Zutphen-van Geffen,
• I Kuan,
• K Koek,
• H Kastrissios,
• K Patel,
• M Davis,
• P Yue

Affiliations

C Mayer

1 Semivida Research, Dallas, UNITED STATES

D Cooper

2 Daniel S Cooper, MD, LLC, Palo Alto, UNITED STATES

A Redfern

3 Linear Clinical Research, Nedlands, AUSTRALIA

X Geng

4 Global Blood Therapeutics, South San Francisco, UNITED STATES

J Shi

4 Global Blood Therapeutics, South San Francisco, UNITED STATES

M Zutphen-van Geffen

5 Certara USA, Inc., Princeton, UNITED STATES

I Kuan

5 Certara USA, Inc., Princeton, UNITED STATES

K Koek

5 Certara USA, Inc., Princeton, UNITED STATES

H Kastrissios

5 Certara USA, Inc., Princeton, UNITED STATES

K Patel

5 Certara USA, Inc., Princeton, UNITED STATES

M Davis

4 Global Blood Therapeutics, South San Francisco, UNITED STATES

P Yue

4 Global Blood Therapeutics, South San Francisco, UNITED STATES